[go: up one dir, main page]

WO1997028181A3 - Stabilisation apres marquage de proteines et de peptides radiomarquees - Google Patents

Stabilisation apres marquage de proteines et de peptides radiomarquees Download PDF

Info

Publication number
WO1997028181A3
WO1997028181A3 PCT/US1997/001695 US9701695W WO9728181A3 WO 1997028181 A3 WO1997028181 A3 WO 1997028181A3 US 9701695 W US9701695 W US 9701695W WO 9728181 A3 WO9728181 A3 WO 9728181A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
labeling
stabilization
post
radiolabeled proteins
Prior art date
Application number
PCT/US1997/001695
Other languages
English (en)
Other versions
WO1997028181A9 (fr
WO1997028181A2 (fr
Inventor
Paul O Zamora
Michael J Marek
Original Assignee
Rhomed Inc
Paul O Zamora
Michael J Marek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhomed Inc, Paul O Zamora, Michael J Marek filed Critical Rhomed Inc
Priority to CA002279349A priority Critical patent/CA2279349C/fr
Priority to AU25264/97A priority patent/AU2526497A/en
Publication of WO1997028181A2 publication Critical patent/WO1997028181A2/fr
Publication of WO1997028181A3 publication Critical patent/WO1997028181A3/fr
Publication of WO1997028181A9 publication Critical patent/WO1997028181A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Utilisation d'acide ascorbique et de ses dérivés pour stabiliser des protéines et des peptides radiomarqués en évitant la perte du radio marquage par oxydation et l'autoradiolyse. L'acide ascorbique est ajouté après le radiomarquage, avec éventuellement la période d'incubation requise, mais avant l'administration au patient.
PCT/US1997/001695 1996-02-02 1997-02-03 Stabilisation apres marquage de proteines et de peptides radiomarquees WO1997028181A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002279349A CA2279349C (fr) 1996-02-02 1997-02-03 Composition pharmaceutique stabilisee avec un ascorbate et methode pour son utilisation
AU25264/97A AU2526497A (en) 1996-02-02 1997-02-03 Post-labeling stabilization of radiolabeled proteins and peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1102796P 1996-02-02 1996-02-02
US60/011,027 1996-05-21

Publications (3)

Publication Number Publication Date
WO1997028181A2 WO1997028181A2 (fr) 1997-08-07
WO1997028181A3 true WO1997028181A3 (fr) 1997-10-09
WO1997028181A9 WO1997028181A9 (fr) 1998-03-05

Family

ID=21748542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/001695 WO1997028181A2 (fr) 1996-02-02 1997-02-03 Stabilisation apres marquage de proteines et de peptides radiomarquees

Country Status (3)

Country Link
AU (1) AU2526497A (fr)
CA (1) CA2279349C (fr)
WO (1) WO1997028181A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992961B2 (en) 1999-02-08 2015-03-31 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AU2002218751A1 (en) * 2000-07-06 2002-01-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
MXPA03007595A (es) * 2001-02-26 2003-12-04 Bristol Myers Squibb Pharma Co Analogos de acido ascorbico para metalorradiofarmaceuticos.
US7238338B1 (en) * 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
CA2683610C (fr) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Formulations en suspension de peptides insulinotropes et leurs utilisations
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
ES2650667T3 (es) 2009-09-28 2018-01-19 Intarcia Therapeutics, Inc Rápido establecimiento y/o terminación de la administración sustancial de fármaco en estado estacionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
EP3426305B1 (fr) * 2016-03-07 2025-05-07 Actinium Pharmaceuticals, Inc. Compositions d'immunoglobulines anti-cd45 radio-marquées stabilisées
EP3458084B1 (fr) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401646A (en) * 1981-05-08 1983-08-30 University Patents Inc. Method and apparatus for purifying materials radiolabeled with technetium-99m
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5308603A (en) * 1990-03-27 1994-05-03 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
US5384113A (en) * 1991-08-29 1995-01-24 Mallinckrodt Medical, Inc. Stabilizers to prevent autoradiolysis of radiolabeled peptides and proteins
US5405597A (en) * 1991-09-10 1995-04-11 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401646A (en) * 1981-05-08 1983-08-30 University Patents Inc. Method and apparatus for purifying materials radiolabeled with technetium-99m
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5308603A (en) * 1990-03-27 1994-05-03 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
US5384113A (en) * 1991-08-29 1995-01-24 Mallinckrodt Medical, Inc. Stabilizers to prevent autoradiolysis of radiolabeled peptides and proteins
US5405597A (en) * 1991-09-10 1995-04-11 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992961B2 (en) 1999-02-08 2015-03-31 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator

Also Published As

Publication number Publication date
AU2526497A (en) 1997-08-22
CA2279349A1 (fr) 1997-08-07
WO1997028181A2 (fr) 1997-08-07
CA2279349C (fr) 2007-09-25

Similar Documents

Publication Publication Date Title
WO1997028181A3 (fr) Stabilisation apres marquage de proteines et de peptides radiomarquees
UA26855C2 (uk) Фармацевтичhа композиція, яка регулює гематопоез
ES2130428T3 (es) Cristales de insulina asp-b28.
AU694229B2 (en) A pharmaceutical preparation comprising glucagon
EP0950665A4 (fr) Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
EP0731712A4 (fr) Compositions physiologiquement stables d'acide butyrique, de sels et de derives d'acide butyrique, utilisees comme agents antineoplasiques
FR2784294B1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
DE19775083I2 (de) 7-Piperazinyl-oder 7-Morpholino-4-oxo-chinolin-3-carbonsaeurederivate ihre Herstellung und ihre Verwendung als antimikrobielle Mittel
IL125800A0 (en) Thermally stabilized contrast agent
HUP0100284A2 (hu) Aktivált protein C készítmények
EP0232849A3 (en) Pyrrolidineamide derivative of acylamino acid, pharmaceutical composition and use
FR2581877B1 (fr) Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
EP0373195A4 (fr) Composition pour accroitre in-vivo ou in-vitro la teneur en melanine des melanocytes et methodes pour utiliser la dite composition.
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
MY136546A (en) A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
ZA975755B (en) Useful formulations of acid addition salt drugs.
ATE203903T1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel
MD980129A (en) Antiherpetic remedy
HUP9802437A3 (en) 5-pyrazolylbenzoic acid derivatives, herbicidal, desiccant and defoliant compositions containing these compounds as active ingredients, preparation and use of the latest
AU5740799A (en) Use of polyaspartic acid in hair-treatment preparations
Glowski Living goddess as incarnate image: The Kumari Cult of Nepal
WO2000027881A3 (fr) Proteines mutees de l'interleukine 10 humaine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WD Withdrawal of designations after international publication

Free format text: US

WD Withdrawal of designations after international publication

Free format text: US

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97527884

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2279349

Country of ref document: CA

Ref country code: CA

Ref document number: 2279349

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase